15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering C4 Therapeutics Inc, 7 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $6.00 to $30.00 (about 5.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $12.17 sits 244% above the current $3.54. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 6 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.25 next quarter toward $-1.04 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Strong Buy
Strong Buy00%
Buy7100%
Hold00%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to C4 Therapeutics Inc.
As of Jul, 7 of 7 firms rate CCCC a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CCCC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.25
Range $-0.29 – $-0.21 · 4 analysts · -15% YoY
Next period, 4 analysts expect C4 Therapeutics Inc to earn $-0.25 a share (range $-0.29 – $-0.21), versus $-0.30 a year earlier. Full-year consensus is $-0.96, growing to $-1.04 the year after.
REVENUE · NEXT QUARTER
$4.6M
Range $0 – $8.3M · 4 analysts · -59% YoY
Revenue is expected to reach $4.6M (range $0 – $8.3M), -59.3% year-over-year. Full-year consensus is $18.9M, rising to $19.1M next year.
Top analysts covering C4 Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CCCC.
#1
Derek Archila
Wells Fargo · Rank #350
Buy
$10.00+182.5% to target
Overall win rate
32%
+ Follow
#2
Etzer Darout
Barclays
Buy
$7.00+97.7% to target
Coverage
—
+ Follow
#3
SL
Sudan Loganathan
Stephens & Co.
Buy
$6.00+69.5% to target
Coverage
—
+ Follow
#4
GC
Gavin Clark-Gartner
Evercore ISI Group
Buy
$12.00+239.0% to target
Coverage
—
+ Follow
#5
Bradley Canino
Guggenheim
Buy
$7.00+97.7% to target
Coverage
—
+ Follow
CCCC stock forecast FAQ
What is CCCC's average 12-month price target?+
The 6 analysts with a live target average $12.17 for C4 Therapeutics Inc over the next 12 months, ranging from a $30.00 high to a $6.00 low.
Is CCCC stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 7 analyst ratings, 7 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CCCC?+
The Street-high target is $30.00 (Brookline Capital), and the Street-low is $6.00 (Stephens & Co.). The average of all 6 active targets is $12.17.
How many Wall Street analysts cover CCCC?+
7 analysts have an active rating on C4 Therapeutics Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering CCCC?+
Among analysts who currently cover CCCC, Derek Archila of Wells Fargo has the strongest overall Quantellect track record (Rank #350). Their current call is Buy with a $10.00 target.
What is C4 Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.25 per share (range $-0.29 – $-0.21) across 4 analysts. Full-year EPS is projected at $-0.96, rising to $-1.04 the following year.
How much revenue is C4 Therapeutics Inc expected to report next quarter?+
Consensus revenue is $4.6M (range $0 – $8.3M). Full-year revenue is projected at $18.9M, growing to $19.1M next year.
Have analysts been upgrading or downgrading CCCC lately?+
As of Jul, 7 of 7 firms rate CCCC a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CCCC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
